|
Market Closed -
London S.E.
11:35:05 2026-09-16 am EDT
|
5-day change | 1st Jan Change | ||
| 1,865.50 GBX | +0.62% |
|
+3.44% | +2.25% |
| 09:55am | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 03:00am | UK inflation rises; Barratt cuts completions outlook | AN |
| Market Cap | 74.29B 99.91B 86.58B 81.83B 139B 9,584B 140B 977B 377B 4,861B 375B 367B 15,495B | P/E 2026 * |
14.2x | P/E 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 94.97B 128B 111B 105B 178B 12,252B 179B 1,249B 483B 6,214B 480B 469B 19,808B | EV / Sales 2026 * |
2.8x | EV / Sales 2027 * | 2.6x |
| Free-Float |
92.75% | Yield 2026 * |
3.75% | Yield 2027 * | 4.04% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
OTC Markets
| GLAXF | Delayed | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Börse Stuttgart
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | +0.58% | ||
| 1 week | +3.44% | ||
| Current month | +0.65% | ||
| 1 month | +0.76% | ||
| 3 months | -4.33% | ||
| 6 months | -7.92% | ||
| Current year | +2.25% |
| 1 week | 1,770 |  | 1,883.5 |
| 1 month | 1,770 | | 1,937 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,455 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/9/26 | Free | Compliance Officer | 7 | 0.0000% | ||
| 9/9/26 | Buy | Executive/Senior Manager | 7 | 0.0000% | ||
| 9/9/26 | Free | Executive/Senior Manager | 7 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.62% | +3.44% | +27.51% | +23.92% | 100B | |
| +0.44% | +1.37% | +49.02% | +99.48% | 1,013B | |
| +0.21% | +0.09% | +51.50% | +64.54% | 644B | |
| -0.08% | +4.86% | +21.66% | +70.91% | 465B | |
| +0.53% | +4.26% | +40.29% | +40.53% | 352B | |
| +0.39% | +2.35% | +17.96% | +24.19% | 264B | |
| +0.17% | +4.17% | +6.96% | +13.12% | 253B | |
| +0.54% | -3.51% | +38.24% | +43.46% | 203B | |
| -1.20% | -5.64% | -24.09% | -58.09% | 188B | |
| +1.54% | +1.73% | +33.66% | +95.95% | 181B | |
| Average | +0.27% | -0.66% | +26.27% | +41.80% | 366.39B | |
| Weighted average by Cap. | +0.25% | +0.10% | +34.29% | +59.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.93B 45.63B 39.55B 37.38B 63.6B 4,378B 63.98B 446B 172B 2,220B 171B 168B 7,078B | 35.5B 47.75B 41.38B 39.11B 66.54B 4,580B 66.94B 467B 180B 2,323B 179B 175B 7,405B |
| Net income | 5.35B 7.19B 6.23B 5.89B 10.02B 690B 10.08B 70.32B 27.17B 350B 27.02B 26.42B 1,115B | 6.28B 8.45B 7.32B 6.92B 11.78B 811B 11.85B 82.64B 31.93B 411B 31.75B 31.04B 1,311B |
| Net Debt | 20.68B 27.81B 24.1B 22.78B 38.76B 2,668B 38.99B 272B 105B 1,353B 104B 102B 4,313B | 17.97B 24.16B 20.94B 19.79B 33.68B 2,318B 33.88B 236B 91.3B 1,176B 90.77B 88.75B 3,748B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-16 | GBX 1,865.50 | +0.62% | 3,784,583 |
| 26-09-15 | GBX 1,854.00 | -0.03% | 4,902,189 |
| 26-09-14 | GBX 1,854.50 | +4.74% | 4,365,927 |
| 26-09-11 | GBX 1,770.50 | -0.28% | 3,934,440 |
| 26-09-10 | GBX 1,775.50 | -1.55% | 3,018,902 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
